Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.56 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.56 |
| ▸ | RHEB | Q15382 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.55 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62398 | 0.81 | DRD4 (0.85) | ROCK2ROCK1DRD4SLC6A12SLC6A13 | |
| SCHEMBL10778977 | 0.79 | ACHE (0.58) | ACHEBCHEMAOAMAOBSIGMAR1 | |
| SCHEMBL25037863 | 0.78 | SMYD3 (0.64) | SIGMAR1DRD4SLC6A12SLC6A13 | |
| SCHEMBL27008240 | 0.78 | SLC6A2 (0.73) | ACHEBCHEMAOAMAOBDRD4 | |
| SCHEMBL650728 | 0.78 | ACHE (0.76) | ACHEMAOAMAOBSIGMAR1DRD4 | |
| SCHEMBL91086 | 0.78 | MAPT (0.48) | ACHEBCHEMAOAMAOBROCK2 | |
| SCHEMBL62009 | 0.76 | SLC6A5 (0.54) | ACHEBCHEMAOAMAOBSIGMAR1 | |
| SCHEMBL31736417 | 0.76 | MCHR1 (0.77) | MAOBSIGMAR1DRD4SLC6A12SLC6A13 | |
| SCHEMBL12971898 | 0.75 | RHEB (0.56) | SIGMAR1DRD4SLC6A12SLC6A13RHEB | |
| SCHEMBL20773510 | 0.74 | SLC6A12 (0.67) | ACHESIGMAR1ROCK2ROCK1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231666-B1 | Carboxamide, sulfonamide and amine compounds for metabolic disorders | RIGEL PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8895578-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140045882-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8557822-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8129390-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2231666-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2009076631-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | ACHE 1975/4885BCHE 1658/4885MAOA 1965/4885 |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | ACHE 1975/4885BCHE 1658/4885MAOA 1965/4885 |
| US-20140045882-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | ACHE 1975/4885BCHE 1658/4885MAOA 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.